Dr Thomas Bieringer to head up Bayer technology centre
May 17, 2011Manufacturing and Production appointment, manufacturing and production
Bayer has appointed Dr Thomas Bieringer as managing director of INVITE GmbH, a joint research venture with the Technical University …
Sanofi strikes Crohn’s deal with Glenmark
May 16, 2011Research and Development Crohn’s disease, Glenmark, Sanofi
Sanofi has signed a deal with Indian drug maker Glenmark Pharmaceuticals to develop a new treatment for Crohn’s Disease. The …
Shield Therapeutics appoints finance chief
May 16, 2011Sales and Marketing appointment, sales and marketing
Swiss specialty pharma company Shield Therapeutics has appointed Richard Jones to the newly-created role of chief financial officer. He has …
Merck’s hepatitis drug Victrelis approved by FDA
May 16, 2011Sales and Marketing Merck & Co, Victrelis, boceprevir, hepatitis C
The FDA has approved Merck’s hepatitis C drug Victrelis, the first oral treatment for the disease. Victrelis (boceprevir) has been …
ABPI and BIA move in together
May 16, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, BIA
The UK’s pharma industry association the ABPI and its biotech equivalent the BIA are jointly relocating to new London offices. …
It’s time we redesigned the clinical trial
May 16, 2011Research and Development clinical trials, randomised controlled trials
Who can remember a time when the pathway from laboratory bench to marketed product didn’t include clinical trial phases I …
Price concession helps change NICE’s mind on Simponi
May 13, 2011Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme
NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
Takeda denies $12bn Nycomed takeover reports
May 13, 2011Research and Development, Sales and Marketing Nycomed, Takeda
Japan’s biggest pharma firm Takeda has denied reports it is negotiating a billion dollar deal to acquire Swiss speciality firm …
EMA under fire from European Parliament
May 13, 2011Medical Communications, Research and Development, Sales and Marketing EMA, European Parliament, MEPs
The EMA has been hit by a barrage of criticism from the European Parliament over conflicts of interest and the …
Publicis acquires Beijing-based healthcare agency
May 13, 2011Medical Communications Publicis Life Brands Dreams, Publicis Life Brands Watermelon, medical communications agency, publicis
Publicis has acquired Dreams Communication, a Chinese agency specialising in healthcare communications. Dreams will become part of Publicis Healthcare Communications …
NHS Alliance defends GP commissioning
May 13, 2011GP commissioning, NHS Alliance, NHS reforms
The NHS Alliance has issued a staunch defence of the principle of GP commissioning – but warned the government to …
GSK and AZ collaborate on translational research centre
May 12, 2011Research and Development AstraZeneca, GlaxoSmithKline, The University of Manchester, academic research, translational research
The University of Manchester has teamed up with GSK and AstraZeneca to create the Manchester Collaborative Centre for Inflammation Research …
SHL Continues to Expand Taiwan Facilities to Support Auto Injector Production
May 12, 2011Manufacturing and Production assembly, auto injector, autoinjector, automation, cnc, shl group
May 12, 2011 [Taoyuan, Taiwan]: SHL has just completed an additional expansion of its Nan Kan 6 facility located in …
Life appoints head of digital
May 12, 2011Medical Communications appointment, medical communications
Faisal Ahmed has joined Berkshire, UK-based comms agency Life as head of digital. Faisal’s digital pedigree includes being part of …
PCTs increasingly ‘red list’ drugs to cut costs
May 12, 2011Sales and Marketing GP prescribing deicisions, GPs, PCTs, prescribing
GPs are being asked not to prescribe NICE-approved drugs in order to cut costs. In the last year more than …
Government wrong to push for Avastin in eye disease, says charity
May 12, 2011Research and Development, Sales and Marketing Lucentis, RNIB, avastin, wet AMD
The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …
Roche aims for wholly personalised skin cancer drug
May 12, 2011Sales and Marketing Roche, personalised medicine, skin cancer, vemurafenib
Roche has submitted its key skin cancer drug vemurafenib to European and American regulators for approval. Vemurafenib (formerly RG7204) has …
AZ signs targeted colon cancer drug collaboration
May 11, 2011Research and Development AstraZeneca, colorectal cancer, personalised medicine
AstraZeneca has entered a partnership which intends to speed up the development of targeted treatments for colorectal cancer, a disease …
Drug regulators protect profits over patients, new study finds
May 11, 2011Research and Development Bad Science, Vioxx, regulatory affairs
Medicine regulators are protecting drug company profits over the welfare of patients by withholding trial data. That’s the verdict of …
New product can overtake Lantus, says Novo leader
May 11, 2011Sales and Marketing Novo Nordisk, degludec, diabetes, insulin
Novo Nordisk’s new insulin product can eclipse Sanofi’s Lantus within just a few years of its launch, according to Novo’s …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
